Trophic serves as a strategic partner for all aspects of communications for life science companies. We apply a deep understanding of both the science and business of drug development and the capital needed for success. Based on breadth and depth of experience, Trophic has become the go-to advisory for presenting corporate stories and scientific concepts. Current client portfolio ranges from biotech start-ups, listed biopharmas and small and large pharmaceutical companies.

TROPHIC TWITTER FEED

Follow us on Twitter to stay tuned on biotech news and the inner workings of the Trophic team

Article from @nytimes confirming the first #BeanoftheMonth – without peer-reviewed publications, novel therapeutic approaches can be misinterpreted & overhyped: https://t.co/QMHzX1eAtJ. #stemcelltherapy #officedog

Article from @nytimes confirming the first #BeanoftheMonth – without peer-reviewed publications, novel therapeutic approaches can be misinterpreted & overhyped: https://t.co/QMHzX1eAtJ. #stemcelltherapy #officedog
Trophic Communications@TrophicComms

Trophic announces the first "Bean of the Month" post for April! On the last day of each month our #officedog, Bean, will delve into industry insights & best practices for #business. Enter the new month w/ tips & tricks for #biotech, #communications & office #fun.

Interesting article from @HarvardBiz illustrating the increasing role of #technology in #healthcare, particularly in rural areas: https://t.co/KAyc65nRVN. #healthtech

Harvard Biz Review@HarvardBiz

Telehealth is increasing rural communities’ access to health care — and it can help urban communities, too. https://t.co/cL4JXIAUea

Today’s #GoogleDoodle celebrates the 159th birthday of Willem Einthoven, the inventor of the Electrocardiogram (#ECG). Einthoven won a Nobel Prize in Medicine in 1924. Happy Birthday!

Load More...